CSL Behring Overview
Company Headquarters: USA
Founded: 2000
Workforce: ~27,000
Revenue: USD 10.56 Billion (December 31, 2021)
Company Working: CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia; hereditary angioedema; inherited respiratory disease; and neurological disorders. CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. Company collaborates with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research. CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity, and superior performance. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries. CSL Limited is the parent company of global biotechnology leader CSL Behring; the world's largest collector of human plasma, CSL Plasma; and global leader in influenza prevention, Seqirus. CSL Limited is based in Melbourne, Victoria, Australia, and is traded on the Australian Securities Exchange (ASX) under the symbol CSL.
Strategy
CSL Behring is a global biotechnology company that specializes in the research, development, and manufacturing of innovative therapies and products for rare and serious diseases. The company's strategy is centered around four key areas:
Patient focus: CSL Behring's primary goal is to develop therapies that address the unmet medical needs of patients with rare and serious diseases. The company works closely with patient organizations and advocacy groups to ensure that patient needs and preferences are at the forefront of its research and development efforts.Innovation: CSL Behring invests heavily in research and development to create innovative therapies and products that improve patient outcomes. The company has a strong pipeline of potential treatments for a range of diseases, including hemophilia, primary immunodeficiency, and neurological disorders.Manufacturing excellence: CSL Behring has a deep understanding of the complex manufacturing processes required to produce high-quality biologics. The company invests in state-of-the-art facilities and processes to ensure that its products meet the highest standards of safety, efficacy, and quality.Global reach: CSL Behring operates in more than 35 countries and has a strong presence in both developed and emerging markets. The company's global footprint allows it to reach more patients and provide access to life-saving therapies in areas of the world where they are needed most.
